Drug Profile
Carbon-11-BU 99008
Alternative Names: [11C]BU99008; BU-99008Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Imperial College of Science, Technology and Medicine
- Developer GSK; Imperial College of Science, Technology and Medicine
- Class Diagnostic agents; Imaging agents
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for phase-0 development in Alzheimer's-disease(Diagnosis) in United Kingdom (IV)
- 27 Aug 2020 GlaxoSmithKline in collaboration with Imperial College London terminates a phase 0 trial in Alzheimer's disease in UK due patient recruitment issues (NCT02874820)
- 28 Sep 2018 No recent reports of development identified for phase-0 development in Alzheimer's-disease(Diagnosis) in United Kingdom (IV)